Gathering the record
Relay is organizing the evidence and source boundaries.
Copper-binding tripeptide complex
A copper-binding peptide studied mainly for hair growth in laboratory experiments.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Cultured human scalp follicles exposed ex vivo showed elongation and growth-related cellular changes; participants were not treated clinically.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Clinical irritation, sensitization, systemic copper exposure, and longer-term cosmetic-use safety are not adequately characterized for standardized AHK-Cu products.
No direct evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNot FDA-approved as a drug; direct evidence is laboratory and ex vivo. Whether a standardized topical formulation improves hair outcomes in controlled human trials and how it compares with established treatments.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Topical · Applied to the skin
Hair-follicle and cell-culture experiments do not establish a human topical concentration or injected dose. GHK-Cu is a different peptide complex.
What would fill this gap: A formulation-specific human study of AHK-Cu.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published research exposed isolated human scalp follicles and cultured cells to AHK-Cu outside the body to examine growth-related laboratory changes.
Population: Cultured human scalp follicles
Design: Ex vivo human hair-follicle and cell study
Mechanisms
AHK-Cu has been evaluated in cultured human hair follicles and dermal-cell systems. Ex vivo human tissue is biologically relevant but is not a clinical treatment study.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Laboratory and ex vivo human-follicle evidence; no controlled clinical efficacy trial located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether a standardized topical formulation improves hair outcomes in controlled human trials and how it compares with established treatments.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Participants were not treated, so this is not a human clinical administration record. The experiment cannot establish topical absorption, visible hair growth, comparative effectiveness, injectable effects, or clinical safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Ex vivo human hair-follicle and cell study
Cultured human scalp follicles
AHK-Cu promoted elongation of isolated cultured human hair follicles and influenced dermal papilla cell behavior.
Study administration: Not stated in the current record.
Limitations: Ex vivo tissue study; no clinical efficacy or safety conclusion.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
A review describes copper-peptide biology and a limited direct clinical evidence base.
Study administration: Not stated in the current record.
Limitations: Mechanistic review; product and peptide-specific evidence varies.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 17703734
PMID 35626037